Mi Lin is an intern for Global Health Governance at the Council on Foreign Relations.
On March 9-10 and March 16-17, two sections of the United Nations Secretary-General’s High-Level Panel on Access to Medicines (UNGSAM) were held in London and Johannesburg, respectively. These two conventions were launched in response to UN Secretary-General Ban Ki-moon’s call last November to “find solutions to the lack of access to medicines.” This was the first time such a high-level panel on access to medicines was made open to the public. Though the two dialogues, one in a developed country and the other in a developing country, had different conversational dynamics, issues surrounding intellectual property (IP) rules in free trade agreements (FTAs) were frequently raised in both sections. Health advocates have long argued that stricter IP provisions in FTAs is a main barrier to access to essential medicines for populations in developing countries. As the recently signed Trans-Pacific Partnership (TPP) adds the latest development to this decades-long debate on trade and health, issues around TPP and its potential effects on global access to medicine also arose frequently at the panel. Read more »